← Back to Search

Enhanced Symptom Management for Cancer

N/A

Recruiting

Led By Ryan W Huey, MD

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adults (>= 18 years) with metastatic thoracic and gastrointestinal (esophagus, stomach, liver, pancreas, small bowel, colon, and rectum) scheduled to initiate outpatient chemotherapy (cycle 1, dose 1) at M D Anderson Cancer Center (MDACC) (Texas Medical Center location)

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to 6 months

Awards & highlights

Study Summary

This trial is testing if providing enhanced symptom management and remote monitoring to patients undergoing chemotherapy can help reduce the number of emergency room visits and hospitalizations.

Who is the study for?

This trial is for adults with metastatic cancers of the thoracic and gastrointestinal regions, starting outpatient chemotherapy at MD Anderson Cancer Center. Caregivers can participate with patient consent. Excluded are those on investigational drugs, in phase 1 trials, requiring inpatient infusion, living in institutions like prisons, or with dementia or disabilities preventing symptom reporting.Check my eligibility

What is being tested?

The study tests if enhanced outpatient symptom management using telemedicine and remote monitoring reduces emergency visits due to chemotherapy side effects compared to usual care. It aims for better patient outcomes including quality of life and fewer treatment delays.See study design

What are the potential side effects?

Since this trial focuses on managing symptoms from standard chemotherapy rather than testing new drugs, it doesn't introduce additional side effects beyond those typically expected from chemotherapy such as nausea, fatigue, hair loss, and increased infection risk.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am an adult with cancer in the chest or digestive system starting chemotherapy at MDACC.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to 6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Rate of acute care visits

Secondary outcome measures

Change in health-related quality of life (HRQOL)

Change in patient engagement

Change in symptom management

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Arm III (standard of care, remote monitoring, biometrics)Experimental Treatment3 Interventions

Patient receive standard of care consisting of oncology care provided via telemedicine. Patients also undergo remote monitoring and biometric monitoring.

Group II: Arm II (standard of care, remote monitoring)Experimental Treatment3 Interventions

Patients receive standard of care consisting of oncology care provided via telemedicine. Patients also undergo remote monitoring.

Group III: Arm I (standard of care)Active Control2 Interventions

Patients receive standard of care consisting of oncology care provided via telemedicine.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Patient Monitoring

2019

N/A

~10

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,972 Previous Clinical Trials

1,786,549 Total Patients Enrolled

Ryan W Huey, MDPrincipal InvestigatorM.D. Anderson Cancer Center

Anaeze Offodile, MDPrincipal InvestigatorM.D. Anderson Cancer Center

Media Library

Enhanced Outpatient Symptom Management with Telemedicine and Remote Monitoring Clinical Trial Eligibility Overview. Trial Name: NCT05038254 — N/A

Rectal Cancer Research Study Groups: Arm III (standard of care, remote monitoring, biometrics), Arm I (standard of care), Arm II (standard of care, remote monitoring)

Rectal Cancer Clinical Trial 2023: Enhanced Outpatient Symptom Management with Telemedicine and Remote Monitoring Highlights & Side Effects. Trial Name: NCT05038254 — N/A

Enhanced Outpatient Symptom Management with Telemedicine and Remote Monitoring 2023 Treatment Timeline for Medical Study. Trial Name: NCT05038254 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the total number of individuals being recruited for this research endeavor?

"Affirmative. The facts presented on clinicaltrials.gov demonstrate this medical research is actively enrolling participants, with 600 people needed at a single site since its initial posting date of May 12th 2021 and latest update dated September 28th 2022."

Answered by AI

Is admission to this scientific study still available?

"Affirmative. Clinicaltrials.gov provides evidence that this trial is currently seeking men and women to participate, with the original post having been made on May 12th 2021 and edited most recently on September 28th 2022. This research project requires 600 volunteers from a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events

2021. "Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05038254.

All > Esophagus Cancer > Gastric Cancer